

24
10/1/01

reactions by purification over Wizard PCR columns (Promega). A second round PCR reaction was performed using 2 μ l of the purified first round reaction. For the second round, the forward primer had the sequence 5'-ACTCACTATAGGGCTCGAGCGGC-3' (nested adaptor primer 2, Clontech) (SEQ ID NO:13), and the reverse primer had the sequence 5'-GTTGGCCACAACACATTTGGGCTTGT-3' (hER β -specific, designated oligo #13871) (SEQ ID NO:11). The second round PCR reaction and cycling conditions were identical to those employed in the first round. The products were cloned into the pCR2.1 vector and two clones were sequenced. The two clones contain insert sequences of different lengths that are homologous to hER β , to each other, and to the sequences isolated from a human ovary cDNA library as described above.

IN THE CLAIMS

Please amend the claims pursuant to 37 C.F.R. §1.121 as follows (see the accompanying "marked-up" version pursuant to 1.121):

17. (Amended) A purified polypeptide comprising a sequence selected from the group consisting of the sequence depicted in Figure 4, SEQ ID NO:2.

Please add the following new claims:

28. The polypeptide of claim 17, wherein the polypeptide is modified with a label capable of providing a detectable signal.

29. The polypeptide of claim 28, wherein the signal is a radioisotope.

30. The polypeptide of claim 28, wherein the signal is a fluorescent

compound.

31. The polypeptide of claim 18, wherein the polypeptide is modified with a label capable of providing a detectable signal.

32. The polypeptide of claim 31, wherein the signal is a radioisotope.

33. The polypeptide of claim 31, wherein the signal is a fluorescent compound.

34. The polypeptide of claim 17, wherein the polypeptide is produced in intact cells.

35. The polypeptide of claim 17, wherein the polypeptide is produced in cell-free translation systems.

36. The polypeptide of claim 18, wherein the polypeptide is produced in intact cells.

37. The polypeptide of claim 18, wherein the polypeptide is produced in cell-free translation systems.

38. The polypeptide of claim 17, wherein the polypeptide is chemically synthesized.

39. The polypeptide of claim 17, wherein the polypeptide is produced in a recombinant system.

40. The polypeptide of claim 18, wherein the polypeptide is chemically synthesized.

41. The polypeptide of claim 18, wherein the polypeptide is produced in